BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25908468)

  • 1. Outcomes of drug-based and surgical treatments for primary aldosteronism.
    Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
    Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.
    Amar L; Baguet JP; Bardet S; Chaffanjon P; Chamontin B; Douillard C; Durieux P; Girerd X; Gosse P; Hernigou A; Herpin D; Houillier P; Jeunemaitre X; Joffre F; Kraimps JL; Lefebvre H; Ménégaux F; Mounier-Véhier C; Nussberger J; Pagny JY; Pechère A; Plouin PF; Reznik Y; Steichen O; Tabarin A; Zennaro MC; Zinzindohoue F; Chabre O
    Ann Endocrinol (Paris); 2016 Jul; 77(3):179-86. PubMed ID: 27315757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary aldosteronism: Practical recommendations for treatment and follow-up.
    Araujo-Castro M; Pascual-Corrales E; Martín Rojas P; Parra Ramírez P
    Hipertens Riesgo Vasc; 2023; 40(4):215-221. PubMed ID: 37993292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine arterial hypertension: therapeutic approach in clinical practice.
    Mazza A; Armigliato M; Zamboni S; Rempelou P; Rubello D; Pessina AC; Casiglia E
    Minerva Endocrinol; 2008 Dec; 33(4):297-312. PubMed ID: 18923367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases.
    Iwakura Y; Morimoto R; Kudo M; Ono Y; Takase K; Seiji K; Arai Y; Nakamura Y; Sasano H; Ito S; Satoh F
    J Clin Endocrinol Metab; 2014 May; 99(5):1593-8. PubMed ID: 24285678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
    Pechère-Bertschi A; Herpin D; Lefebvre H
    Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
    Carey RM
    Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism.
    Rossi GP; Cesari M; Cuspidi C; Maiolino G; Cicala MV; Bisogni V; Mantero F; Pessina AC
    Hypertension; 2013 Jul; 62(1):62-9. PubMed ID: 23648698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
    Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
    Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary aldosteronism].
    Amar L
    Rev Prat; 2015 Jun; 65(6):817-21. PubMed ID: 26298907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
    Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
    Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
    Marzano L; Colussi G; Sechi LA; Catena C
    Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary hyperaldosteronism.
    Araujo-Castro M
    Med Clin (Barc); 2020 Oct; 155(7):302-308. PubMed ID: 32586668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.
    Williams TA; Reincke M
    Eur J Endocrinol; 2018 Jul; 179(1):R19-R29. PubMed ID: 29674485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
    Kline GA; Pasieka JL; Harvey A; So B; Dias VC
    Ann Surg Oncol; 2013 Jul; 20(7):2274-8. PubMed ID: 23504117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of successful outcome in patients with primary aldosteronism.
    Moo TA; Zarnegar R; Duh QY
    Curr Treat Options Oncol; 2007 Aug; 8(4):314-21. PubMed ID: 18058076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Medical Treatment of Primary Aldosteronism.
    Li YJ; Ji ZG; Wen J
    Chin Med Sci J; 2023 Mar; 38(1):49-56. PubMed ID: 36642703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.